Atlas Venture Associates XI’s Intellia Therapeutics NTLA Stock Holding History

Atlas Venture Associates XI’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$87.9M	Buy	+1,615,321	New	+$58.7M	13.93%	2

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Atlas Venture Associates XI's NTLA Position: Q4 2020 in Review

Atlas Venture Associates XI opened a new position in Intellia Therapeutics (NTLA) in Q4 2020: 1,615,321 shares worth $87.9M. The stake represents 13.93% of the portfolio and ranks #2 among its holdings.

241 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

Atlas Venture Associates XI held 1,615,321 shares of Intellia Therapeutics worth $87.9M as of Q4 2020.
Intellia Therapeutics was a new Atlas Venture Associates XI position in Q4 2020.
Intellia Therapeutics made up 13.93% of Atlas Venture Associates XI's portfolio in Q4 2020, its #2 holding.
241 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on Atlas Venture Associates XI's 13F filing for Q4 2020, filed 1 Feb 2021.